Acalabrutinib Patent Expiration
Acalabrutinib is used for treating adult patients with various types of leukemia and lymphoma. It was first introduced by Astrazeneca Uk Ltd
Acalabrutinib Patents
Given below is the list of patents protecting Acalabrutinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Calquence | US10167291 | Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide | Jul 01, 2036 | Astrazeneca |
| Calquence | US9796721 | Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide | Jul 01, 2036 | Astrazeneca |
| Calquence | US10272083 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | Jan 21, 2035 | Astrazeneca |
| Calquence | US11771696 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | Jan 21, 2035 | Astrazeneca |
| Calquence | US10239883 | 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors | Jul 11, 2032 | Astrazeneca |
| Calquence | US9290504 | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors | Jul 11, 2032 | Astrazeneca |
| Calquence | US9758524 | 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors | Jul 11, 2032 | Astrazeneca |
| Calquence | US7459554 | Imidazopyrazine tyrosine kinase inhibitors | Nov 24, 2026 | Astrazeneca |
Acalabrutinib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List